Literature DB >> 2415970

Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.

C A Fulcher, S de Graaf Mahoney, J R Roberts, C K Kasper, T S Zimmerman.   

Abstract

Epitopes for 22 alloantibodies that inhibit factor VIII procoagulant protein (FVIII) from multitransfused individuals with severe hemophilia A and three autoantibodies from nonhemophilic individuals appeared to be restricted to two specific regions of the FVIII molecule. Immunoblotting of purified FVIII and purified thrombin-degraded FVIII, followed by reaction with inhibitor plasma samples, monoclonal anti-human IgG3 and IgG4 antibodies, and radiolabeled affinity-purified rabbit anti-mouse IgG, revealed that inhibitor epitopes could be localized to the Mr 72,000 and Mr 44,000 thrombin fragments of FVIII. These two chains are located at the carboxyl terminus and near the amino terminus of the FVIII molecule, respectively. The pattern of reactivity of the inhibitor alloantibodies could be divided into three types: 10 reacted with the Mr 72,000 chain, 3 reacted with the Mr 44,000 chain, and 9 reacted with both of these chains. Among the 3 inhibitor autoantibodies, 1 of each type was found. Ten normal plasmas, as well as 14 plasmas from multitransfused individuals with severe hemophilia A and no inhibitor, were not reactive with the FVIII immunoblots. However, one multitransfused individual with severe hemophilia A and no detectable inhibitor revealed the presence of an antibody reactive with the middle section of the FVIII molecule. The existence of FVIII inhibitor epitopes on both the Mr 72,000 and Mr 44,000 chains raises the possibility that these epitopes might be further restricted to regions of homology between the two chains. These data suggest the possibility of designing inhibitor blocking polypeptides for use as therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2415970      PMCID: PMC391407          DOI: 10.1073/pnas.82.22.7728

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Letter: A more uniform measurement of factor VIII inhibitors.

Authors: 
Journal:  Thromb Diath Haemorrh       Date:  1975-12-15

2.  Immunologic studies of antihemophilic factor (AHF, VIII:C). VI. Characterization of antigenic determinants using human antibodies.

Authors:  M S Gawryl; L W Hoyer
Journal:  Clin Immunol Immunopathol       Date:  1982-05

3.  "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

Authors:  W N Burnette
Journal:  Anal Biochem       Date:  1981-04       Impact factor: 3.365

4.  Molecular cloning of a cDNA encoding human antihaemophilic factor.

Authors:  J J Toole; J L Knopf; J M Wozney; L A Sultzman; J L Buecker; D D Pittman; R J Kaufman; E Brown; C Shoemaker; E C Orr
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

5.  Studies on the relationship between factor VIII related antigen (VIIIRAg) and factor VIII clotting antigen (VIIICAg) by immunoelectrophoresis and autoradiography using 125I anti VIIICAg.

Authors:  B L Davies; R A Furlong; I R Peake
Journal:  Thromb Res       Date:  1981 Apr 1-15       Impact factor: 3.944

6.  Management of inhibitors to factor VIII.

Authors:  C K Kasper
Journal:  Prog Hematol       Date:  1981

7.  Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody.

Authors:  C A Fulcher; T S Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

8.  Porcine factor VIII:C prepared by affinity interaction with von Willebrand factor and heterologous antibodies: sodium dodecyl sulfate polyacrylamide gel analysis.

Authors:  G J Knutson; D N Fass
Journal:  Blood       Date:  1982-03       Impact factor: 22.113

9.  Thrombin-catalyzed activation of human coagulation factor V.

Authors:  K Suzuki; B Dahlbäck; J Stenflo
Journal:  J Biol Chem       Date:  1982-06-10       Impact factor: 5.157

10.  Monoclonal antibodies to porcine factor VIII coagulant and their use in the isolation of active coagulant protein.

Authors:  D N Fass; G J Knutson; J A Katzmann
Journal:  Blood       Date:  1982-03       Impact factor: 22.113

View more
  24 in total

1.  Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis.

Authors:  M Higuchi; S E Antonarakis; L Kasch; J Oldenburg; E Economou-Petersen; K Olek; M Arai; H Inaba; H H Kazazian
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 2.  Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.

Authors:  Jun-ichi Ori; Ichiro Tanaka; Yoko Kubota; Midori Shima; Tomoko Matsumoto; Koichi Yoshida; Yoshihiko Sakurai; Akira Yoshioka
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

3.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

Authors:  M Arai; D Scandella; L W Hoyer
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

4.  Kappa/lambda immunoglobulin distribution in Graves' thyroid-stimulating antibodies. Simultaneous analysis of C lambda gene polymorphisms.

Authors:  R C Williams; N J Marshall; K Kilpatrick; J Montano; P M Brickell; M Goodall; P A Ealey; B Shine; A P Weetman; R K Craig
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

Review 5.  Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.

Authors:  Géraldine Lavigne-Lissalde; Chantal Rothschild; Claire Pouplard; Priscilla Lapalud; Yves Gruel; Jean-François Schved; Claude Granier
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

6.  Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A.

Authors:  Jisu Oh; Yeongmin Lim; Moon Ju Jang; Ji Young Huh; Midori Shima; Doyeun Oh
Journal:  Blood Res       Date:  2013-03-25

7.  Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.

Authors:  J Batlle; E Gómez; E Rendal; J Torea; E Lourés; M Couselo; P Vila; C Sedano; X Tusell; M Magallón; M Quintana; R González-Boullosa; M F López-Fernández
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

8.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

Review 9.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

10.  Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

Authors:  P Lollar; E T Parker; J E Curtis; S L Helgerson; L W Hoyer; M E Scott; D Scandella
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.